Suspended

Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease

What is being tested

Atorvastatin

Drug

Who is being recruted

Cardiovascular Diseases+2

+ Coronary Disease

+ Heart Diseases

Over 18 Years

+4 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Prevention Study

Placebo-ControlledPhase 4

Interventional

Study Start: June 2009

See protocol details

Summary

Principal SponsorYonsei University

Study ContactHyuk-Jae Chang, MD, PhD

Last updated: January 27, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: June 1, 2009

Actual date on which the first participant was enrolled.

The aim of this prospective study is to investigate the prevalence of endothelial dysfunction in subjects with family history of premature coronary heart disease. At the same time, the effect of atorvastatin in treating subclinical endothelial dysfunction in those patients will be evaluated.

Official TitleRandomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease

NCT00917527

Principal SponsorYonsei University

Study ContactHyuk-Jae Chang, MD, PhD

Last updated: January 27, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

77 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Cardiovascular DiseasesCoronary DiseaseHeart DiseasesVascular DiseasesMyocardial Ischemia

Criteria

2 inclusion criteria required to participate

within 1 year

the siblings of premature coronary heart disease(male<55years old, female<65years old: Framingham Heart Study)patients admitted relevant hospital

2 exclusion criteria prevent from participating

Documented coronary heart disease

Any woman of childbearing potential who is pregnant, seeking to become pregnant or suspects that she may be pregnant.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental

Group II

Placebo

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Severance Cardiovascular Hospital, Yonsei University College of Medicine

Seoul, South KoreaOpen Severance Cardiovascular Hospital, Yonsei University College of Medicine in Google Maps

SuspendedOne Study Center